MCID: CYT008
MIFTS: 57

Cytomegalovirus Infection

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Cytomegalovirus Infection

MalaCards integrated aliases for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 53 3 17
Cytomegalovirus Infections 42 71

Classifications:



External Ids:

UMLS 71 C0010823

Summaries for Cytomegalovirus Infection

NINDS : 53 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to congenital cytomegalovirus and colitis, and has symptoms including fever and pruritus. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Triamcinolone and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

MedlinePlus : 42 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50 percent and 80 percent of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. About one out of every 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV infection will have long-term health problems.

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1190)
# Related Disease Score Top Affiliating Genes
1 congenital cytomegalovirus 34.1 TNF IL1B CCL2
2 colitis 31.4 TNF IL6 IL1B CXCL8
3 cytomegalovirus retinitis 31.3 TNF HLA-B HLA-A
4 ulcerative colitis 31.3 TNF IL6 IL1B CXCL8
5 vasculitis 31.2 TNF IL6 HLA-B CCL2
6 bronchiolitis obliterans 31.0 TNF IL6 CXCL8
7 cerebral palsy 31.0 TNF IL6 IL1B CXCL8
8 toxoplasmosis 30.9 TNF IL6 IL1B CCL3
9 exanthem 30.9 TNF MTOR IL6 IL1B CXCL8
10 myelitis 30.9 TNF IL6 CXCL8
11 intestinal perforation 30.9 TNF NFKB1 IL6
12 graft-versus-host disease 30.9 TNF IL6 IL1B HLA-B HLA-A FAS
13 lymphopenia 30.9 RAG1 IL6 FAS B2M
14 iridocyclitis 30.8 TNF IL6 HLA-B
15 rubella 30.8 TNF IL6 IL1B HLA-B HLA-A
16 acquired immunodeficiency syndrome 30.8 TNF IL6 IL1B HLA-B CCL3 B2M
17 gastroenteritis 30.8 TNF IL6 IL1B CXCL8
18 perinatal necrotizing enterocolitis 30.8 TNF IL6 IL1B CXCL8
19 polyradiculopathy 30.8 TNF IL6 IL1B
20 chlamydia 30.8 TNF IL6 IL1B CXCL8 CCL2
21 esophagitis 30.8 TNF IL6 IL1B CXCL8 CCL5
22 crohn's disease 30.8 TNF IL6 IL1B CXCL8 CCL2
23 cystitis 30.8 TNF IL6 CXCL8 CCL2
24 gastritis 30.8 TNF IL6 IL1B CXCL8 CCL5
25 herpes simplex 30.7 TNF IRF3 IL6 HLA-B CCL5
26 hepatitis a 30.7 TNF IL1B CXCL8
27 viral hepatitis 30.7 TNF IL6 IL1B FAS
28 erythema multiforme 30.7 TNF IL6 FAS CXCL8
29 hemorrhagic cystitis 30.7 TNF IL1B HLA-A
30 crohn's colitis 30.7 TNF IL1B CXCL8
31 toxic shock syndrome 30.7 TNF IL6 IL1B CXCL8
32 arteries, anomalies of 30.7 TNF IL6 IL1B CCL2
33 pharyngitis 30.6 TNF IL6 IL1B CXCL8
34 autoimmune hepatitis 30.6 TNF IL6 HLA-A FAS
35 diarrhea 30.6 TNF IRF3 IL6 IL1B CXCL8
36 chlamydia pneumonia 30.6 TNF IL6 IL1B CXCL8 CCL2
37 pericarditis 30.6 TNF IL6 IL1B CXCL8
38 polyneuropathy 30.6 TNF IL6 IL1B B2M
39 transverse myelitis 30.6 TNF IL6 CXCL8
40 cholangitis 30.6 TNF IL6 HLA-B CXCL8
41 meningoencephalitis 30.6 TNF IL6 IL1B CCL5 B2M
42 autoimmune myocarditis 30.6 TNF CCL2
43 neonatal jaundice 30.6 TNF IL6 IL1B
44 lymphocytic choriomeningitis 30.6 IRF3 IL6 CXCL8
45 respiratory failure 30.6 TNF IL6 IL1B CXCL8 CCL5
46 central nervous system vasculitis 30.6 TNF IL6 IL1B
47 atherosclerosis susceptibility 30.6 TNF IL6 IL1B CXCL8 CCL2
48 syphilis 30.5 TNF IL6 FAS B2M
49 acute pancreatitis 30.5 TNF IL6 IL1B CXCL8
50 bacterial sepsis 30.5 TNF IL6 IL1B CXCL8

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


fever, pruritus

GenomeRNAi Phenotypes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.6 HLA-A HLA-B HLA-G
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.6 HLA-A HLA-B HLA-G
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.6 HLA-A HLA-B HLA-G
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.6 HLA-A HLA-B HLA-G
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.6 HLA-A HLA-B HLA-G
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.6 HLA-A HLA-B HLA-G HLA-E
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.6 HLA-E
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.6 HLA-A HLA-B HLA-G
9 Decreased viability with paclitaxel GR00179-A-1 9.55 MTOR SP1
10 Decreased viability with paclitaxel GR00179-A-2 9.55 MTOR
11 Decreased viability with paclitaxel GR00179-A-3 9.55 MTOR SP1
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CASP3 CXCL8 FAS IL1B NFKB1 SP1
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CASP3 CXCL8 FAS IL1B NFKB1 SP1
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 NFKB1
15 Increased viability with paclitaxel GR00179-A-1 8.65 CASP3

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 B2M CASP3 CCL5 FAS HLA-A HLA-E
2 homeostasis/metabolism MP:0005376 10.17 B2M CASP3 CREB1 FAS HLA-E HLA-G
3 cardiovascular system MP:0005385 10.13 B2M CASP3 CREB1 FAS IL1B IL6
4 immune system MP:0005387 10.13 B2M CASP3 CCL2 CCL5 FAS HLA-A
5 endocrine/exocrine gland MP:0005379 10.1 B2M CASP3 CREB1 FAS HLA-A IL6
6 integument MP:0010771 9.81 B2M CASP3 FAS IL1B IL6 NFKB1
7 respiratory system MP:0005388 9.65 CASP3 CREB1 FAS IL6 IRF3 MTOR
8 skeleton MP:0005390 9.32 CASP3 CREB1 FAS IL1B IL6 MTOR

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
6
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
7
Pancrelipase Approved, Investigational Phase 4 53608-75-6
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Azathioprine Approved Phase 4 446-86-6 2265
11
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
13
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
14
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
15
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
16
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
17
Dolutegravir Approved Phase 4 1051375-16-6 54726191
18
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
19 Immunoglobulins Phase 4
20 Antibodies Phase 4
21 Triamcinolone diacetate Phase 4
22 triamcinolone acetonide Phase 4
23 Triamcinolone hexacetonide Phase 4
24 Antiviral Agents Phase 4
25 Vaccines Phase 4
26 Liver Extracts Phase 4
27 Hydrocortisone 17-butyrate 21-propionate Phase 4
28
dipyrone Phase 4 522325
29 Hydrocortisone hemisuccinate Phase 4
30 Anti-Arrhythmia Agents Phase 4
31 Tocolytic Agents Phase 4
32 Anticonvulsants Phase 4
33 Calcium, Dietary Phase 4
34 Anesthetics Phase 4
35 calcium channel blockers Phase 4
36 pancreatin Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Ophthalmic Solutions Phase 4
39 Anti-HIV Agents Phase 4
40 Integrase Inhibitors Phase 4
41 HIV Integrase Inhibitors Phase 4
42
protease inhibitors Phase 4
43 HIV Protease Inhibitors Phase 4
44 valacyclovir Phase 4
45
Calcium Nutraceutical Phase 4 7440-70-2 271
46
acetic acid Approved Phase 3 64-19-7 176
47
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
48
Acyclovir Approved Phase 3 59277-89-3 2022
49
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
50
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098

Interventional clinical trials:

(show top 50) (show all 308)
# Name Status NCT ID Phase Drugs
1 An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients. Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
3 The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
4 Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients. Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
5 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients Completed NCT01552369 Phase 4 Valganciclovir
6 Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
7 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
8 A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
9 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
10 A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®). Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
11 A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
12 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
13 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
14 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
15 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
16 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
17 Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
18 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
19 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
20 Prospective Comparative Study of the Humoral and Cell-Mediated Immune Responses to the Trivalent Subviron Influenza Vaccine in Pediatric Liver Transplant Recipients as an Indicator for Response of Immunocompromised Subjects to Vaccination Against Agents of Bioterrorism Completed NCT00133510 Phase 4
21 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial Completed NCT01651585 Phase 4 Valacyclovir arrow
22 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
23 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
24 A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT) Completed NCT02550639 Phase 4
25 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
26 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
27 Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone Recruiting NCT03468478 Phase 4 Sirolimus;Everolimus;Mycophenolic acid
28 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
29 Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC Not yet recruiting NCT04278547 Phase 4
30 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
31 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
32 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
33 The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group Unknown status NCT02005822 Phase 3 Valganciclovir
34 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
35 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
36 Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy. Completed NCT04067869 Phase 3
37 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Completed NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
38 Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
39 A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
40 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
41 A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) Completed NCT00466817 Phase 3 Valganciclovir
42 A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant Completed NCT01077908 Phase 3 Best available antiviral drug therapy
43 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir;Valganciclovir
44 A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes) Completed NCT00001038 Phase 3 Valacyclovir hydrochloride;Acyclovir
45 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Completed NCT00411645 Phase 3 maribavir
46 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates Completed NCT00000584 Phase 3 immunoglobulins
47 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. Completed NCT00001100 Phase 3 ganciclovir
48 A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation Completed NCT00227370 Phase 3 valganciclovir
49 A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants Completed NCT00497796 Phase 3 maribavir;ganciclovir
50 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cidofovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Foscarnet
Foscarnet Sodium Hexahydrate
Ganciclovir
Ganciclovir Sodium
Immunoglobulins, Intravenous
valganciclovir
Valganciclovir hydrochloride

Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

40
Kidney, Liver, T Cells, Bone, Heart, Bone Marrow, Lung

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 9350)
# Title Authors PMID Year
1
Diagnosing congenital Cytomegalovirus infection: don't get rid of dried blood spots. 61 42
32164599 2020
2
SARS-CoV-2: Is it the newest spark in the TORCH? 42
32335336 2020
3
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. 42
32286644 2020
4
Immunoselective algorithm to devise multi-epitope subunit vaccine fighting against human cytomegalovirus infection. 61
32165246 2020
5
Can network pharmacology identify the anti-virus and anti- inflammatory activities of Shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection? 61
32501408 2020
6
Diagnosis-independent loss of T-cell costimulatory molecules in individuals with cytomegalovirus infection. 61
32209361 2020
7
Etiological profile of hearing loss amongst Lithuanian pediatric cochlear implant users. 61
32305661 2020
8
Should hearing targeted screening for congenital cytomegalovirus infection Be implemented? 61
32361556 2020
9
Do Antivirals Improve Hearing Outcomes in Neonates With Congenital Cytomegalovirus Infection? 61
32010980 2020
10
Neurodevelopmental outcomes of infants with congenital cytomegalovirus infection in Western Kenya. 61
32388467 2020
11
Prospective multicenter comparison of urine culture with PCR on dried blood spots using 2 different extraction and PCR methods in neonates suspected for congenital cytomegalovirus infection. 61
32408061 2020
12
The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis. 61
31644496 2020
13
Epstein-Barr Virus and Cytomegalovirus Infections of the Liver. 61
32389366 2020
14
Hygiene promotion might be better than serological screening to deal with Cytomegalovirus infection during pregnancy: a methodological appraisal and decision analysis. 61
32546244 2020
15
Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature. 61
32257152 2020
16
Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis. 61
32570217 2020
17
Prediction of Neurodevelopmental Impairment in Congenital Cytomegalovirus Infection by Early Postnatal Magnetic Resonance Imaging. 61
32492677 2020
18
The Dysfunctional Immune System in Common Variable Immunodeficiency Increases the Susceptibility to Gastric Cancer. 61
32575504 2020
19
Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant. 61
32112710 2020
20
Immune Monitoring Using QuantiFERON®-CMV Assay in Congenital Cytomegalovirus Infection: Correlation With Clinical Presentation and CMV DNA load. 61
32504086 2020
21
Cotton wool balls are an effective urine collection tool for CMV PCR for diagnosing congenital cytomegalovirus infection. 61
32334829 2020
22
Controversies in the therapeutic approach to congenital cytomegalovirus infection. 61
32125680 2020
23
Late Conversion to Sirolimus or Everolimus After Pancreas Transplant. 61
32213293 2020
24
Pediatric encephalic ultrasonography: the essentials. 61
30552663 2020
25
Polytrauma in a geriatric patient resulting in reactivation of cytomegalovirus infection and secondary cold agglutinin disease-induced haemolytic anaemia. 61
32554607 2020
26
Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis. 61
32573886 2020
27
Impairment in neurocognitive function following experimental neonatal guinea pig cytomegalovirus infection. 61
32555536 2020
28
CytoMegaloVirus Infection Database: A Public Omics Database for Systematic and Comparable Information of CMV. 61
31813095 2020
29
[Different viral doses of cytomegalovirus infection in the left and right colons]. 61
32486535 2020
30
Kidney function of Japanese children undergoing kidney transplant with preemptive therapy for cytomegalovirus infection. 61
32108410 2020
31
Cytomegalovirus infection after kidney transplantation during 16 years in South Korea. 61
32379946 2020
32
Can cytomegalovirus infection affect male reproductive function? Results of a retrospective single-centre analysis. 61
32510732 2020
33
Risk factors for new-onset diabetes mellitus after kidney transplantation: A systematic review and meta-analysis. 61
32506801 2020
34
Pneumatosis intestinalis in COVID-19. 61
32522754 2020
35
Prevention of Acquisition of Cytomegalovirus Infection in Pregnancy Through Hygiene-based Behavioral Interventions: A Systematic Review and Gap Analysis. 61
32502127 2020
36
Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients. 61
32567256 2020
37
Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy. 61
32144592 2020
38
If Biliary Atresia Is a Disease Starting In Utero: Should We Treat Ongoing Cytomegalovirus Infection or Not? 61
32443054 2020
39
Disseminated Tularemia: Finding the Needle in the Haystack. 61
32535620 2020
40
Clinical consequences of primary CMV infection after renal transplantation: a case-control study. 61
32480425 2020
41
Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study. 61
32506738 2020
42
The Aquaporin3 Promoter Polymorphism -1431 A/G is Associated with Acute Graft Rejection and Cytomegalovirus Infection in Kidney Recipients Due to Altered Immune Cell Migration. 61
32521638 2020
43
Valacyclovir in primary maternal CMV infection for prevention of vertical transmission: A case-series. 61
32325395 2020
44
Congenital infections as contributors to the onset of diabetes in children: A longitudinal study in the United States, 2001-2017. 61
31820549 2020
45
How to Treat Cytomegalovirus-induced Hemophagocytic Lymphohistiocytosis in a Child With Leukemia. 61
31306340 2020
46
Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. 61
32363972 2020
47
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. 61
32320566 2020
48
Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program. 61
32035273 2020
49
Low birth weight and head circumference as potential biomarkers of sensorineural hearing loss in asymptomatic congenitally CMV-infected infants. 61
32521464 2020
50
The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with Pneumocystis jirovecii pneumonia. 61
31994768 2020

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF RAG1 NFKB1 MTOR IRF3 IL6
2
Show member pathways
13.97 TNF NFKB1 MTOR IL6 IL1B FAS
3
Show member pathways
13.81 TNF NFKB1 MTOR IL6 IL1B FAS
4
Show member pathways
13.69 TNF SP1 NFKB1 MTOR IL6 IL1B
5
Show member pathways
13.56 NFKB1 MTOR HLA-G HLA-E HLA-B HLA-A
6
Show member pathways
13.55 TNF SP1 NFKB1 MTOR IL6 IL1B
7
Show member pathways
13.45 TNF NFKB1 MTOR IL6 IL1B FAS
8
Show member pathways
13.44 TNF NFKB1 IL6 IL1B FAS CXCL8
9
Show member pathways
13.32 TNF SP1 NFKB1 MTOR IL6 IL1B
10
Show member pathways
13.22 TNF NFKB1 MTOR IL6 FAS CCL5
11
Show member pathways
13.16 TNF NFKB1 IRF3 IL6 IL1B FAS
12
Show member pathways
13.05 TNF NFKB1 MTOR IRF3 IL6 HLA-G
13 13.01 SP1 NFKB1 MTOR IL6 FAS CXCL8
14
Show member pathways
13 NFKB1 FAS CXCL8 CCL5 CCL3 CCL2
15
Show member pathways
12.97 TNF RAG1 NFKB1 IRF3 IL6 IL1B
16
Show member pathways
12.9 TNF SP1 NFKB1 IRF3 IL6 IL1B
17
Show member pathways
12.89 TNF IL6 IL1B HLA-G HLA-E HLA-B
18
Show member pathways
12.87 TNF NFKB1 MTOR IL6 CREB1
19 12.86 TNF NFKB1 IL1B FAS CASP3
20
Show member pathways
12.84 TNF NFKB1 IRF3 IL6 IL1B HLA-G
21
Show member pathways
12.83 TNF SP1 NFKB1 IL1B FAS CREB1
22
Show member pathways
12.82 NFKB1 MTOR FAS CREB1 CASP3
23
Show member pathways
12.81 TNF NFKB1 IRF3 FAS CASP3
24
Show member pathways
12.78 TNF NFKB1 FAS CREB1 CASP3
25
Show member pathways
12.77 TNF NFKB1 MTOR IL6 IL1B FAS
26 12.75 TNF RAG1 NFKB1 IRF3 IL1B FAS
27 12.72 TNF NFKB1 MTOR IRF3 IL6 IL1B
28
Show member pathways
12.71 TNF NFKB1 MTOR IL6 IL1B
29
Show member pathways
12.71 IRF3 HLA-G HLA-E HLA-B HLA-A B2M
30
Show member pathways
12.7 TNF NFKB1 IL6 IL1B CCL2
31
Show member pathways
12.7 TNF NFKB1 IL1B FAS CASP3
32
Show member pathways
12.69 TNF HLA-G HLA-E HLA-B HLA-A FAS
33
Show member pathways
12.67 NFKB1 IRF3 IL6 IL1B CCL5
34
Show member pathways
12.66 SP1 NFKB1 MTOR IL1B CREB1 CASP3
35
Show member pathways
12.65 SP1 NFKB1 IL6 IL1B CREB1
36
Show member pathways
12.6 HLA-G HLA-E HLA-B HLA-A B2M
37 12.58 TNF NFKB1 MTOR IRF3 IL1B CXCL8
38
Show member pathways
12.55 TNF SP1 NFKB1 IL6 IL1B CXCL8
39
Show member pathways
12.52 TNF IL6 CXCL8 CCL5 CCL3 CCL2
40
Show member pathways
12.51 TNF NFKB1 IL6 IL1B CCL5 CCL2
41 12.51 NFKB1 IRF3 HLA-G HLA-E HLA-B HLA-A
42
Show member pathways
12.5 TNF NFKB1 IRF3 IL6 IL1B CXCL8
43
Show member pathways
12.49 SP1 NFKB1 CREB1 CCL2
44 12.49 TNF NFKB1 IL6 IL1B CXCL8 CASP3
45
Show member pathways
12.47 TNF IRF3 IL6 IL1B HLA-G HLA-E
46
Show member pathways
12.46 NFKB1 MTOR CREB1 CCL2 CASP3
47 12.46 TNF NFKB1 IL6 IL1B FAS CXCL8
48 12.45 TNF NFKB1 IL6 HLA-G HLA-E HLA-B
49
Show member pathways
12.43 SP1 NFKB1 MTOR CREB1
50 12.43 TNF NFKB1 IRF3 IL6 IL1B CXCL8

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.15 TNF NFKB1 IL6 IL1B HLA-G HLA-E
2 extracellular space GO:0005615 10.13 TNF IL6 IL1B HLA-G HLA-E CXCL8
3 Golgi membrane GO:0000139 9.95 MTOR HLA-G HLA-E HLA-B HLA-A B2M
4 cell surface GO:0009986 9.93 TNF HLA-E HLA-B HLA-A FAS B2M
5 external side of plasma membrane GO:0009897 9.89 TNF HLA-G HLA-E FAS B2M
6 early endosome membrane GO:0031901 9.8 HLA-G HLA-E HLA-B HLA-A B2M
7 recycling endosome membrane GO:0055038 9.65 HLA-G HLA-E HLA-B HLA-A B2M
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.62 HLA-G HLA-E HLA-B HLA-A
9 phagocytic vesicle membrane GO:0030670 9.55 HLA-G HLA-E HLA-B HLA-A B2M
10 MHC class I peptide loading complex GO:0042824 9.52 HLA-A B2M
11 death-inducing signaling complex GO:0031264 9.51 FAS CASP3
12 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-G HLA-E HLA-B HLA-A B2M
13 MHC class I protein complex GO:0042612 9.02 HLA-G HLA-E HLA-B HLA-A B2M

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 NFKB1 IL6 IL1B FAS CXCL8 CREB1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNF SP1 NFKB1 IRF3 IL6 IL1B
3 immune system process GO:0002376 10.22 IRF3 HLA-G HLA-E HLA-B HLA-A B2M
4 positive regulation of transcription, DNA-templated GO:0045893 10.18 TNF SP1 NFKB1 IRF3 IL6 IL1B
5 innate immune response GO:0045087 10.17 NFKB1 IRF3 HLA-E HLA-B HLA-A B2M
6 viral process GO:0016032 10.16 SP1 IRF3 HLA-E HLA-B HLA-A CREB1
7 positive regulation of gene expression GO:0010628 10.13 TNF SP1 MTOR IL6 IL1B CCL3
8 inflammatory response GO:0006954 10.13 TNF NFKB1 IL6 IL1B CXCL8 CCL5
9 positive regulation of apoptotic process GO:0043065 10.11 TNF IL6 FAS CREB1 CASP3
10 MAPK cascade GO:0000165 10.06 TNF IL1B CCL5 CCL3 CCL2
11 cytokine-mediated signaling pathway GO:0019221 10.06 TNF IL6 IL1B CXCL8 CCL5 CCL3
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.04 TNF CCL5 CCL3 CCL2
13 regulation of immune response GO:0050776 10.04 HLA-G HLA-E HLA-B HLA-A B2M
14 cellular response to lipopolysaccharide GO:0071222 10.04 TNF NFKB1 IRF3 IL6 IL1B CXCL8
15 positive regulation of protein phosphorylation GO:0001934 10.03 TNF MTOR IL1B FAS
16 chemotaxis GO:0006935 10.01 CXCL8 CCL5 CCL3 CCL2
17 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 TNF NFKB1 IL6 IL1B
18 cellular response to tumor necrosis factor GO:0071356 10 NFKB1 CXCL8 CCL5 CCL3 CCL2
19 cellular response to interleukin-1 GO:0071347 9.97 NFKB1 CXCL8 CCL5 CCL3 CCL2
20 neutrophil chemotaxis GO:0030593 9.97 IL1B CXCL8 CCL5 CCL3 CCL2
21 defense response to Gram-positive bacterium GO:0050830 9.96 TNF IL6 HLA-E HLA-A
22 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.96 HLA-G HLA-E HLA-B HLA-A B2M
23 type I interferon signaling pathway GO:0060337 9.95 IRF3 HLA-G HLA-E HLA-B HLA-A
24 cellular response to mechanical stimulus GO:0071260 9.93 NFKB1 IL1B FAS
25 chemokine-mediated signaling pathway GO:0070098 9.93 CXCL8 CCL5 CCL3 CCL2
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNF IL6 CCL5
27 regulation of insulin secretion GO:0050796 9.92 TNF IL1B CCL5
28 apoptotic signaling pathway GO:0097190 9.92 TNF FAS CASP3
29 positive regulation of smooth muscle cell proliferation GO:0048661 9.92 TNF MTOR IL6 CCL5
30 response to glucocorticoid GO:0051384 9.91 TNF IL6 CASP3
31 protein kinase B signaling GO:0043491 9.91 TNF IL1B CCL5 CCL3 CCL2
32 positive regulation of T cell proliferation GO:0042102 9.9 IL6 IL1B CCL5
33 humoral immune response GO:0006959 9.9 TNF IL6 CCL2
34 positive regulation of neuron apoptotic process GO:0043525 9.9 TNF CCL3 CASP3
35 positive regulation of interleukin-6 production GO:0032755 9.9 TNF IL6 IL1B
36 monocyte chemotaxis GO:0002548 9.9 IL6 CCL5 CCL3 CCL2
37 visual learning GO:0008542 9.89 RAG1 MTOR CREB1
38 positive regulation of interferon-gamma production GO:0032729 9.88 TNF IL1B HLA-A
39 positive regulation of epithelial to mesenchymal transition GO:0010718 9.88 MTOR IL6 IL1B
40 negative regulation of neurogenesis GO:0050768 9.88 TNF IL6 IL1B B2M
41 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF MTOR IL1B
42 antigen processing and presentation GO:0019882 9.87 HLA-E HLA-B HLA-A
43 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.86 IL1B FAS CASP3
44 lymphocyte chemotaxis GO:0048247 9.85 CCL5 CCL3 CCL2
45 cellular response to fibroblast growth factor stimulus GO:0044344 9.85 CXCL8 CCL5 CCL2
46 interferon-gamma-mediated signaling pathway GO:0060333 9.85 IRF3 HLA-G HLA-E HLA-B HLA-A B2M
47 positive regulation of JAK-STAT cascade GO:0046427 9.84 TNF IL6 CCL5
48 positive regulation of glial cell proliferation GO:0060252 9.84 TNF MTOR IL6 IL1B
49 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.83 HLA-G HLA-E HLA-B HLA-A B2M
50 eosinophil chemotaxis GO:0048245 9.82 CCL5 CCL3 CCL2

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.26 TNF SP1 RAG1 NFKB1 MTOR IRF3
2 protein homodimerization activity GO:0042803 9.97 SP1 RAG1 IRF3 HLA-G CCL5 B2M
3 signaling receptor binding GO:0005102 9.91 HLA-G HLA-E HLA-B HLA-A CCL2
4 transcription regulatory region DNA binding GO:0044212 9.77 TNF SP1 NFKB1 IRF3 CREB1
5 identical protein binding GO:0042802 9.7 TNF RAG1 NFKB1 MTOR IRF3 HLA-G
6 chemokine activity GO:0008009 9.62 CXCL8 CCL5 CCL3 CCL2
7 CCR chemokine receptor binding GO:0048020 9.58 CCL5 CCL3 CCL2
8 T cell receptor binding GO:0042608 9.56 HLA-E HLA-A
9 beta-2-microglobulin binding GO:0030881 9.55 HLA-E HLA-A
10 CCR5 chemokine receptor binding GO:0031730 9.54 CCL5 CCL3
11 phospholipase activator activity GO:0016004 9.52 CCL5 CCL3
12 CCR1 chemokine receptor binding GO:0031726 9.48 CCL5 CCL3
13 CD8 receptor binding GO:0042610 9.46 HLA-G HLA-A
14 peptide antigen binding GO:0042605 9.46 HLA-G HLA-E HLA-B HLA-A
15 TAP binding GO:0046977 9.43 HLA-B HLA-A
16 cytokine activity GO:0005125 9.17 TNF IL6 IL1B CXCL8 CCL5 CCL3

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....